- Trials with a EudraCT protocol (8)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
8 result(s) found for: Advanced glycation end-products.
Displaying page 1 of 1.
| EudraCT Number: 2004-000799-15 | Sponsor Protocol Number: 04-04074 | Start Date*: 2004-09-09 |
| Sponsor Name:Aker University Hospital | ||
| Full Title: DOES BENFOTIAMINE SUPPLEMENTATION REDUCE SERUM LEVELS OF ADVANCED GLYCATION END PRODUCTS AND BIOCHEMICAL MARKERS OF VASCULAR DYSFUNCTION IN TYPE 1 DIABETES? | ||
| Medical condition: Type 1 diabetes | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NO (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-000319-27 | Sponsor Protocol Number: ALT-711-0527 | Start Date*: 2007-07-02 | |||||||||||
| Sponsor Name:Alteon, Inc. | |||||||||||||
| Full Title: A Double-blind, Placebo-Controlled, Randomized Trial Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients with Chronic Heart Failure | |||||||||||||
| Medical condition: Heart Failure | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-004995-17 | Sponsor Protocol Number: NL7507301820 | Start Date*: 2021-03-11 |
| Sponsor Name:AMsterdam UMC-AMC | ||
| Full Title: Low dose iron chelation as TReatment of Oxidative stress in Sickle cell disease; TROS study | ||
| Medical condition: Sickle cell disease (an hereditary hemoglobinopathy) | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-001172-15 | Sponsor Protocol Number: APN01-01-COVID19 | Start Date*: 2020-04-08 |
| Sponsor Name:APEIRON Biologics AG | ||
| Full Title: Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19 | ||
| Medical condition: Severe COVID-19 POSITIVE hospitalized male or female, between 18 and ≤ 80 years of age | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) DK (Completed) AT (Completed) GB (GB - no longer in EU/EEA) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-003818-24 | Sponsor Protocol Number: DC2015RED01 | Start Date*: 2015-12-11 |
| Sponsor Name:VU University Medical Center | ||
| Full Title: A phase 4, monocenter, randomized, double-blind, comparator-controlled, parallel-group, mechanistic intervention trial to assess the effect of 12-week treatment with the sodium-glucose linked trans... | ||
| Medical condition: Type 2 Diabetes Mellitus | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-001936-12 | Sponsor Protocol Number: MD2014.01 | Start Date*: 2019-02-11 | ||||||||||||||||
| Sponsor Name:Sanquin Plasma Products BV | ||||||||||||||||||
| Full Title: Efficacy and Safety of human apotransferrin in patients with β-thalassemia | ||||||||||||||||||
| Medical condition: Beta thalassemia intermedia | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: NL (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2017-001547-12 | Sponsor Protocol Number: DC2017RACELINES01 | Start Date*: 2017-12-21 |
| Sponsor Name:VU University Medical Center | ||
| Full Title: A phase 4, monocenter, randomized, double-blind, comparator-controlled, 3-armed parallel mechanistic intervention trial to assess the effect of 8-week empagliflozin (SGLT-2 inhibitor) monotherapy, ... | ||
| Medical condition: Type 2 Diabetes Mellitus | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-001394-29 | Sponsor Protocol Number: 31998 | Start Date*: 2007-12-28 | |||||||||||
| Sponsor Name:Baxter Healthcare Corporation | |||||||||||||
| Full Title: Multi-center, prospective trial to demonstrate Improved Metabolic control of PPEN vs DDDD in DIAbetic CAPD patients -The IMPENDIA Trial | |||||||||||||
| Medical condition: End stage renal disease patients with Diabetes Type I and II on Continuous Ambulatory Peritoneal Dialysis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) PT (Prematurely Ended) AT (Completed) IT (Prematurely Ended) CZ (Completed) ES (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.